Literature DB >> 12835730

Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications.

D González1, A Balanzategui, R García-Sanz, N Gutiérrez, C Seabra, J J M van Dongen, M González, J F San Miguel.   

Abstract

DH-JH rearrangements of the Ig heavy-chain gene (IGH) occur early during B-cell development. Consequently, they are detected in precursor-B-cell acute lymphoblastic leukemias both at diagnosis and relapse. Incomplete DJH rearrangements have also been occasionally reported in mature B-cell lymphoproliferative disorders, but their frequency and immunobiological characteristics have not been studied in detail. We have investigated the frequency and characteristics of incomplete DJH as well as complete VDJH rearrangements in a series of 84 untreated multiple myeloma (MM) patients. The overall detection rate of clonality by amplifying VDJH and DJH rearrangements using family-specific primers was 94%. Interestingly, we found a high frequency (60%) of DJH rearrangements in this group. As expected from an immunological point of view, the vast majority of DJH rearrangements (88%) were unmutated. To the best of our knowledge, this is the first systematic study describing the incidence of incomplete DJH rearrangements in a series of unselected MM patients. These results strongly support the use of DJH rearrangements as PCR targets for clonality studies and, particularly, for quantification of minimal residual disease by real-time quantitative PCR using consensus JH probes in MM patients. The finding of hypermutation in a small proportion of incomplete DJH rearrangements (six out of 50) suggests important biological implications concerning the process of somatic hypermutation. Moreover, our data offer a new insight in the regulatory development model of IGH rearrangements.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12835730     DOI: 10.1038/sj.leu.2402964

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

1.  Improved clonality assessment in germinal centre/post-germinal centre non-Hodgkin's lymphomas with high rates of somatic hypermutation.

Authors:  Mark A Catherwood; David Gonzalez; Caroline Patton; Edwina Dobbin; Lakshmi Venkatraman; H Denis Alexander
Journal:  J Clin Pathol       Date:  2006-06-30       Impact factor: 3.411

Review 2.  Malleable immunoglobulin genes and hematopathology - the good, the bad, and the ugly: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.

Authors:  Adam Bagg
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

3.  Partial versus productive immunoglobulin heavy locus rearrangements in chronic lymphocytic leukemia: implications for B-cell receptor stereotypy.

Authors:  Eugenia Tsakou; Andreas Agathangelidis; Andreas Agathagelidis; Myriam Boudjoghra; Thorsten Raff; Antonis Dagklis; Maria Chatzouli; Tatjana Smilevska; George Bourikas; Helene Merle-Beral; Eleni Manioudaki-Kavallieratou; Achilles Anagnostopoulos; Monika Brüggemann; Frederic Davi; Kostas Stamatopoulos; Chrysoula Belessi
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

4.  Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma.

Authors:  Herbert García-Castillo; Evelia Leal-Ugarte; Pablo César Ortiz Lazareno; Esperanza Barrera-Chairez; Víctor Hugo Rosales-García; Patricio Barros-Núñez
Journal:  Med Oncol       Date:  2014-03-01       Impact factor: 3.064

5.  Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

Authors:  N Puig; M E Sarasquete; A Balanzategui; J Martínez; B Paiva; H García; S Fumero; C Jiménez; M Alcoceba; M C Chillón; E Sebastián; L Marín; M A Montalbán; M V Mateos; A Oriol; L Palomera; J de la Rubia; M B Vidriales; J Bladé; J J Lahuerta; M González; J F S Miguel; R García-Sanz
Journal:  Leukemia       Date:  2013-07-17       Impact factor: 11.528

6.  Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms.

Authors:  Maria E Arcila; Wayne Yu; Mustafa Syed; Hannah Kim; Lidia Maciag; JinJuan Yao; Caleb Ho; Kseniya Petrova; Christine Moung; Paulo Salazar; Ivelise Rijo; Tessara Baldi; Ahmet Zehir; Ola Landgren; Jae Park; Mikhail Roshal; Ahmet Dogan; Khedoudja Nafa
Journal:  J Mol Diagn       Date:  2018-12-25       Impact factor: 5.568

7.  Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemia.

Authors:  Ana Henriques; Arancha Rodríguez-Caballero; Wendy G Nieto; Anton W Langerak; Ignacio Criado; Quentin Lécrevisse; Marcos González; Maria L Pais; Artur Paiva; Julia Almeida; Alberto Orfao
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

8.  A systematic approach for peptide characterization of B-cell receptor in chronic lymphocytic leukemia cells.

Authors:  Paula Díez; Nieves Ibarrola; Rosa M Dégano; Quentin Lécrevisse; Arancha Rodriguez-Caballero; Ignacio Criado; Wendy G Nieto; Rafael Góngora; Marcos González; Julia Almeida; Alberto Orfao; Manuel Fuentes
Journal:  Oncotarget       Date:  2017-06-27

9.  Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.

Authors:  Caleb Ho; Mustafa Syed; Mikhail Roshal; Kseniya Petrova-Drus; Christine Moung; Jinjuan Yao; Andres E Quesada; Jamal Benhamida; Chad Vanderbilt; Ying Liu; Menglei Zhu; Wayne Yu; Lidia Maciag; Meiyi Wang; Yuanyuan Ma; Qi Gao; Even H Rustad; Malin Hultcrantz; Benjamin T Diamond; Binbin Zheng-Lin; Ying Huang; Kasey Hutt; Jeffrey E Miller; Ahmet Dogan; Khedoudja Nafa; Ola Landgren; Maria E Arcila
Journal:  J Mol Diagn       Date:  2020-11-17       Impact factor: 5.568

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.